industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.


July 22nd, 2015

Selecting the Right Valve Types to Improve Process Cooling: New ASCO Whitepaper

FLORHAM PARK, N.J., July 22, 2015 — Help for engineers with selecting the right valve types to help improve process cooling throughout a range of industries is available in a new whitepaper that uses winemaking to illustrate the suggested tradeoffs and advantages involved in optimum valve selection.

The new paper, “Great Wine Coolers: Selecting valves to improve process cooling in winemaking and other industries,” explains that while the cooling process in industrial winemaking is fairly straightforward, it can highlight how valves can function as surprisingly important ingredients in improving a wide variety of process cooling applications.

Key takeaways from the whitepaper include:

  • The multiple choices in selecting valve types for any type of industrial cooling application
  • Diaphragm valves are popular and affordable; may encounter plugging problems
  • Ball valves avoid plugging; are relatively expensive and maintenance-intensive
  • Angle-body piston valves are slightly more expensive than diaphragm valves; offer exceptionally long life
  • An exclusive direct-acting temperature control valve, though initially expensive, provides ultimate economy and most advanced control

Download the free whitepaper, “Great Wine Coolers: Selecting valves to improve process cooling in winemaking and other industries,” at https://goo.gl/SD7RET, from ASCO Numatics, the world’s leading manufacturer of comprehensive fluid automation, flow control, and pneumatics solutions.

About ASCO Numatics

ASCO Numatics, an Emerson company, offers comprehensive fluid automation solutions, including fluid control and fluid power products, for a wide range of industry-focused applications. The ASCO Numatics product line in North America consists of more than 50,000 valves, an extensive selection of air preparation equipment, and a full line of actuation products. ASCO products include solenoid pilot valves, angle body piston valves, linear indicators, redundant control systems, and pressure sensors. The Numatics line covers valve manifolds, cylinders, grippers, filters, regulators, and lubricators. For more information about ASCO Numatics products, visit www.asconumatics.com.

About Emerson

Emerson (NYSE: EMR), based in St. Louis, Missouri (USA), is a global leader in bringing technology and engineering together to provide innovative solutions for customers in industrial, commercial, and consumer markets around the world.  The company is comprised of five business segments: Process Management, Industrial Automation, Network Power, Climate Technologies, and Commercial & Residential Solutions. Sales in fiscal 2014 were $24.5 billion. For more information, visit Emerson.com.

Tags: , , ,


July 20th, 2015

Free Literature News: SPECTROSCOUT Portable ED-XRF Analyzers

SCOUT Family pg1FREE brochure details new SPECTROSCOUT portable ED-XRF analyzers that bring lab-quality elemental analysis for field or offsite testing for environmental screening, petrochemical exploration as well as laboratory and at-line quality control (QC) testing for processed and manufactured goods (chemicals, oil, metal surface coatings, pharmaceuticals, cosmetics, food, feedstock, etc.).

SPECTRO ANALYTICAL INSTRUMENTS
1.800.548.5809
http://xrf.spectro.com/wp-content/uploads/brochure_spectroscout_family.pdf

 

Tags: , , , , , , , , , , , , , , , ,


July 13th, 2015

PathMaker Neurosystems Receives Milestone Achievement Award for $200,000 from Massachusetts Life Sciences Center

PMNBoston, MA (July 13, 2015) PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing novel non-invasive systems for the treatment of neuromotor disorders, today announced that it is the recipient of a Milestone Achievement Program (MAP) award from the Massachusetts Life Sciences Center (MLSC).  The MAP award, in the amount of $200,000, will enable PathMaker to initiate engineering and development of a clinical-use version of its first product, MyoRegulatorTM, intended for the treatment of spasticity and muscle tone disorders in patients with neuromotor dysfunction. 

“The PathMaker team is honored to have been recognized with the MAP award,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker.  “The support of the MLSC MAP program will enable us to finance critical activities needed in preparation for human clinical trials.  The MLSC has developed an internationally-recognized model for catalyzing innovation that has been instrumental to the success of numerous life science companies based in the Commonwealth.”

PathMaker Neurosystems Inc. was founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. tsDCS is a novel modality for non-invasive neuromodulation that has only emerged within the last five years, being driven by fundamentally new understandings of spinal circuit biology made by PathMaker’s scientific advisors and their clinical work in treating patients with paralysis, muscle weakness and muscle tone disorders.  More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.

The Massachusetts Life Sciences Center (MLSC) is a quasi-governmental investment agency that supports life sciences innovation, research, development and commercialization.  “We are pleased to be able to facilitate the efforts of PathMaker Neurosystems, an innovative neuromodulation company headquartered in Boston, Massachusetts,” said Pamela Norton, Vice President for Industry Relations and Programs at the MLSC. “We look forward to working with PathMaker as they advance a new generation of non-invasive technology for treating patients with neuromotor conditions.”

This announcement is not intended to be a commercial endorsement by the MLSC of any products or services provided or developed by the entities referenced in this release

About PathMaker Neurosystems Inc.

PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.  For more information, please visit www.pmneuro.com.

About Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit www.masslifesciences.com.

 

Tags: , , , , , , ,


July 7th, 2015

At-Line Micronutrient Analysis Using ED-XRF Spectroscopy is Detailed in New Application Brief

Kleve, Germany — July 7, 2015 — The ability to conduct at-line micronutrient analysis using ED-XRF spectroscopy at the point of production is detailed in a new application brief from SPECTRO Analytical Instruments, available to download at http://xrf.spectro.com/micronutrient.

The brief, At-Line Micronutrient Analysis Using ED-XRF Spectroscopy at the Point of Production,” details the significant advantages of at-line elemental analysis for product and consistency in micronutrient analysis — while maximizing production throughput.

Both the recent use of inductively coupled plasma-optical emission spectrometry (ICP-OES) and alternate colorimetric methods for manufacturing quality control purposes present drawbacks for producers, according to the paper. These include the need to transport samples from the production line to a laboratory for analysis, and the lengthy time that is required for extensive sample preparation.

In contrast, the advantages of at-line elemental analysis are many. The foremost benefit, according to the brief, is that with a new-generation portable ED-XRF spectrometer, elemental analysis can be performed directly on a sample and usually with little preparation — at the production line or anywhere in the plant.

In addition, the use of a new, carefully-selected ED-XRF instrument in performing at-line elemental analysis can deliver the level of accuracy previously found only in the laboratory. Moreover, the paper notes, employing at-line elemental analysis can help boost production throughput, reduce costs, and provide the manufacturing process with far more flexibility than ever before.

As a guide, the brief also provides a series of critical factors for readers to consider when specifying and comparing various at-line ED-XRF spectrometers for micronutrient analysis.

The new application brief, “At-Line Micronutrient Analysis Using ED-XRF Spectroscopy at the Point of Production,” is available for download at http://xrf.spectro.com/micronutrient. The application brief is authored by SPECTRO Analytical Instruments, a leading global supplier of analytical instruments for optical emission and X-ray fluorescence spectrometry.

About SPECTRO:

SPECTRO, a unit of the Materials Analysis Division of AMETEK, Inc., manufactures advanced instruments, develops the best solutions for elemental analysis for a broad range of applications, and provides exemplary customer service.

SPECTRO’s products are known for their superior technical capabilities that deliver measureable benefits to the customer. From its foundation in 1979 until today, more than 30,000 analytical instruments have been delivered to customers around the world.

AMETEK, Inc. is a leading global manufacturer of electronic instruments and electromechanical products with more than 15,000 colleagues at nearly 150 operating locations and sales and service operations in the United States and 30 other countries around the world.

Tags: , , , , ,


June 19th, 2015

PathMaker Neurosystems Inc. Named as Healthcare Semi-Finalist in Hello Tomorrow Challenge Global Start-Up Competition

BOSTON, June 19, 2015 – PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing novel non-invasive systems for the treatment of neuromotor disorders, announced that it was named as one of five healthcare semi-finalists selected to advance to the finale of the “Hello Tomorrow” Challenge, the global start-up competition, being held June 24-26.

Hello Tomorrow” is a global competition covering all major fields of technology that promotes the most innovative breakthrough technologies being developed by entrepreneurs who are taking on the most important challenges in the world today. This year, there were 3,600 proposal submitted from 90 countries.

PathMaker Neurosystems was selected as one of only five healthcare semi-finalists selected to present next week in the competition finale. “The PathMaker team is tremendously excited and honored to be invited to present as a semi-finalist at the Hello Tomorrow Challenge,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “Our technology prototypes have already changed the lives of numerous patients with neuromotor dysfunction.  We are committed to rapidly moving forward our pioneering non-invasive technology so that we can treat a global backlog of patients waiting for a therapy that can help them.”

PathMaker Neurosystems Inc. was founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. tsDCS is a novel modality for non-invasive neuromodulation that has only emerged within the last five years, being driven by fundamentally new understandings of spinal circuit biology made by our Company’s scientific advisors and their clinical work in treating patients with paralysis, muscle weakness and muscle tone disorders.  More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.

About PathMaker Neurosystems Inc.
PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.  For more information, please visit www.pmneuro.com.

Tags: , , , , , ,


June 17th, 2015

ASCO Introduces 362 and 562 Series Stainless Steel Spool Valves for Valve Automation in Oil and Gas Markets

ASCO 362 and 562Florham Park, New Jersey, U.S.A., (June 17, 2015) — ASCO Numatics has introduced the 362 and 562 Series of stainless steel spool valves for control valve automation in the upstream, midstream, and downstream oil and gas markets.

“The 362 and 562 Series valves incorporate ASCO’s proven solenoid technology for unequaled reliability in mission-critical oil and gas applications,” said Robert W. Kemple, Jr., executive vice president, sales and marketing – Americas, ASCO Numatics. “Unlike some competitors, we design and manufacture our own solenoids to ensure the highest quality and longest product life.”

The 362 and 562 Series valves offer low-power solenoid versions that consume only 1.4 watts, making them the most energy-efficient valves in their class. A 0.55 watt solenoid option is coming soon that will be ideal for remote applications requiring alternate energy sources.

The ASCO 562 Series is a four-way spool valve designed for double-acting process valves. The 362 Series is a three-way valve made for single-acting process valve applications. Both valve lines are available in ¼-inch, 316L stainless steel construction for corrosion resistance in harsh environments.

“Our new valves have extensive manual and low-temperature versions,” said Kemple. “In addition, ASCO’s solenoid options include a low-power solenoid with UL, CSA, ATEX, and IECEX hazardous location approvals that will support global designs. This flexibility makes the 362 and 562 Series spool valves ideal for a wide variety of upstream and mid-stream oil and gas, plus downstream hydrocarbon and petrochemical processing applications,” he said.

Popular constructions will be available for same-day shipping with no expediting fees via ASCO Express. The valves can be ordered through ASCO distributors and sales representatives. For more information, contact ASCO at 800-972-ASCO (2726), by e-mail at info-valve@ascovalve.com, or visit www.ascovalve.com/spoolvalve.

About ASCO Numatics

ASCO Numatics, an Emerson company, offers comprehensive fluid automation solutions, including fluid control and fluid power products, for a wide range of industry-focused applications. The ASCO Numatics product line in North America consists of more than 50,000 valves, an extensive selection of air preparation equipment, and a full line of actuation products. ASCO products include solenoid pilot valves, angle body piston valves, linear indicators, redundant control systems, and pressure sensors. The Numatics line covers valve manifolds, cylinders, grippers, filters, regulators, and lubricators. For more information about ASCO Numatics products, visit www.asconumatics.com.

About Emerson

Emerson (NYSE: EMR), based in St. Louis, Missouri (USA), is a global leader in bringing technology and engineering together to provide innovative solutions for customers in industrial, commercial, and consumer markets around the world.  The company is comprised of five business segments: Process Management, Industrial Automation, Network Power, Climate Technologies, and Commercial & Residential Solutions. Sales in fiscal 2014 were $24.5 billion. For more information, visit Emerson.com.

Tags: , ,


June 16th, 2015

SPECTRO Introduces SPECTROLAB Spectrometers for Ultimate Performance in Metal Analysis

Kleve, Germany —June 16, 2015 — SPECTRO Analytical Instruments today introduced two new SPECTROLAB Arc/Spark optical emission spectrometers for high-performance metal analysis.

The new SPECTROLAB metal analyzers deliver ultrahigh speed of measurement, ultralow limits of detection, ultimate elemental flexibility, spectacular stability, and affordable cost of ownership to set new standards for elemental analysis in metals industry research and development (R&D) and process/quality control.

The new hybrid SPECTROLAB metal analyzer combines analog photomultiplier tube (PMT) detectors with digital charge coupled device (CCD) technology for ultra-accurate simultaneous measurements in R&D, trace metal measurement, and precious metals analysis.

The new breakthrough all-CCD technology SPECTROLAB spectrometer for metal analysis provides outstanding speed, accuracy, and flexibility for process control and QC of fabricated and finished goods.

Features of both new high-performance metal analyzers include:

  • Spectacular stability without compromise. Unlike conventional models, SPECTROLAB’s sealed, no-purge optical system maximizes light transmission stability, even in the far UV; its software utilizes sophisticated online drift correction measures; and its optimum correlation between analytical and reference lines provides the most stable measurement approach possible.
  • Ultralow limits of detection with improved background correction. Depending on application and analytes, SPECTROLAB can easily ascertain trace values in single parts per million (ppm).
  • Ultrahigh speed of measurement. The coupling of a high-energy plasma generator with SPECTRO’s unique dynamic pre-burn process delivers a lightning fast setup, accelerated sample throughput, and extremely low time to measurement in many applications.
  • Ultimate elemental flexibility, in most cases eliminating hardware reconfigurations. An optional software-extendable configuration enables changes to the elemental setup without requiring calibration.
  • Affordable cost of ownership. iCAL logic saves not only time but also cost for standardization samples. UV-PLUS purification eliminates expensive argon purging or vacuum pumps. Component relocations, advanced diagnostics, and other improvements ease maintenance and prevent downtime.
  • Excellent ease of use with a new user interface and new application profiles that are tailored to predetermined user requirements.

Both new SPECTROLAB high-performance OES spectrometers for metal analysis are immediately available from SPECTRO Analytical Instruments. For more information, visit http://www.spectro.com/lab or email spectro.info@ametek.com.

In addition, join the live webinar broadcast, “Metalmorphosis: Sparking a Revolution in High Performance Metal Analysis” on July 16, 2015, at 1:30 p.m. EDT. Register now at: http://oes.spectro.com/spectrolab/webinar.

SPECTRO Analytical Instruments is a leading global supplier of analytical instruments employing X-ray fluorescence, Arc/Spark, ICP-OES, and ICP-MS technology for the elemental analysis of materials in industry, research, and academia.

About SPECTRO:

SPECTRO, a unit of the Materials Analysis Division of AMETEK, Inc., manufactures advanced instruments, develops the best solutions for elemental analysis for a broad range of applications, and provides exemplary customer service.

SPECTRO’s products are known for their superior technical capabilities that deliver measureable benefits to the customer. From its foundation in 1979 until today, more than 30,000 analytical instruments have been delivered to customers around the world.

AMETEK, Inc. is a leading global manufacturer of electronic instruments and electromechanical products with more than 15,000 colleagues at nearly 150 operating locations and sales and service operations in the United States and 30 other countries around the world.

Tags: , , , , ,


June 16th, 2015

New Portable SPECTROSCOUT X-ray Fluorescence Spectrometer Delivers Fast Lab-Quality Results for At-Line Elemental Analysis

Kleve, Germany — June 15, 2015 — SPECTRO Analytical Instruments today announced the introduction of the new portable SPECTROSCOUT X-ray fluorescence spectrometer that brings laboratory-quality elemental composition monitoring and quality control testing to at-line analysis.

The durable and compact SPECTROSCOUT XRF analyzer delivers reliable and highly precise results with the power of a top-grade laboratory benchtop instrument in an easily transportable design. The SPECTROSCOUT is ideal for manufacturers and processors of such products as chemicals, cosmetics, feedstocks, foods, metal coatings, and pharmaceuticals among others

Employing the SPECTROSCOUT for at-line analysis dramatically enhances QC productivity by eliminating time spent transporting samples from the plant floor to the laboratory to wait in queue for testing. In contrast, the SPECTROSCOUT can deliver audit-traceable results directly from the manufacturing floor.

Moreover, the SPECTROSCOUT is a much more affordable alternative as an at-line installation than larger and more costly laboratory instruments, and it can be operated with minimal introductory training.

Features of the new portable SPECTROSCOUT X-ray fluorescence include:

  • Dependable accuracy and sensitivity at a wide range of detection levels, providing precise at-line analysis from high-percentage concentrations to trace elements.
  • Performance levels that surpass those of other portable spectrometers at a highly competitive cost that is half that of a dedicated laboratory instrument.
  • Ease-of-operation that includes an intuitive interface, simplified software that interacts via a standard computer, and predefined applications packages.
  • Unique iCAL calibration takes just a single integrated sample and 5 minutes, reducing recalibration work.
  • Laboratory-instrument class advantages, ranging from customer-specific calibrations to advanced pre-calibrated application packages.
  • Rugged, lightweight (12 kg/26.46 lb) space-savings design (350 x 306 x 306 mm/13.8 x 12.1 x 12.1 in), that optionally includes a 5-hour internal battery for plant floor, at-line analysis as well as X-ray fluorescence analysis anywhere from the laboratory to the field.

The portable SPECTROSCOUT X-ray fluorescence spectrometer is immediately available from SPECTRO Analytical Instruments. For more information, including a variety of application notes, visit the SPECTROSCOUT Resource Center on the Web at http://xrf.spectro.com/spectroscout, or email spectro.info@ametek.com.

In addition, join the live webinar broadcast,Get Lab-quality QC analysis right at the point of production – with new SPECTROSCOUT on July 9, 2015, at 11:00 a.m. EDT. Register now at: http://xrf.spectro.com/spectroscout/at-line/webinar.

SPECTRO Analytical Instruments is a leading global supplier of analytical instruments employing X-ray fluorescence, Arc/Spark, ICP-OES, and ICP-MS technology for the elemental analysis of materials in industry, research, and academia.

About SPECTRO:

SPECTRO, a unit of the Materials Analysis Division of AMETEK, Inc., manufactures advanced instruments, develops the best solutions for elemental analysis for a broad range of applications, and provides exemplary customer service.

SPECTRO’s products are known for their superior technical capabilities that deliver measureable benefits to the customer. From its foundation in 1979 until today, more than 30,000 analytical instruments have been delivered to customers around the world.

AMETEK, Inc. is a leading global manufacturer of electronic instruments and electromechanical products with more than 15,000 colleagues at nearly 150 operating locations and sales and service operations in the United States and 30 other countries around the world.

Tags: , , , , , ,


June 1st, 2015

Symbiotix Biotherapies Announces $2.3 Million Award from NIH’s National Institute of Allergy and Infectious Diseases (NIAID)


Symbiotix logoBoston, Mass. – June 1, 2015 –
Symbiotix Biotherapies, Inc. (“Symbiotix”) today announced that it was awarded a $2.3 million Phase 2 Small Business Technology Transfer (STTR) Program award from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The company, based in Boston, is developing a novel class of molecular therapeutics from the human microbiome.

Symbiotix’ lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome and the $2.3 million NIH award enables the completion of key translational studies and production of material needed to take into human clinical trials as a novel treatment for multiple sclerosis (MS), said Prof. Lloyd Kasper, Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College, and Co-Founder of Symbiotix.

PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10.

“Current FDA-approved therapies for multiple sclerosis offer only partial benefit for reduction of relapses and time to disability. However, all of these FDA-approved treatments have side effects some of which can be rather profound,” said Prof. Kasper. “We are developing PSA as a safe and effective new oral therapy for the over 500,000 US patients with multiple sclerosis. We expect PSA to have few, if any, significant side effects as it is derived from a commensal bacterial molecule that has evolved to modulate our immune system”.

The studies funded through this prestigious award will be conducted by Symbiotix in collaboration with the Geisel School of Medicine at Dartmouth College

“Our receipt of this third NIH award enables us to move PSA towards human clinical studies as a first-in-class oral treatment for multiple sclerosis,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of Symbiotix. “We are grateful for the continued support by NIH as we translate years of promising academic research funded by NIH into a breakthrough therapy for MS and other immune-mediated diseases”.

About Symbiotix Biotherapies, Inc.

Symbiotix Biotherapies, Inc. was founded on the basis of over a decade of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College, and our Company’s scientific founders are distinguished thought leaders in the microbiome field. At Symbiotix, we are developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. Our lead program represents the first molecule to emerge from the human microbiome and is a first-in-class oral agent for the treatment of serious immune-mediated diseases. For more information, please visit www.symbiotix-bio.com.


May 26th, 2015

Dr. John Spengler to Receive ASHRAE’S 2015 Environmental Health Award

SpenglerJ_1Needham, Mass. — May 26, 2015 — Dr. John D. Spengler, co-founder and Principal of Environmental Health & Engineering (EH&E), a leading provider of environmental and engineering consulting services, and Director of the Center for Health and the Global Environment, and Professor of Environmental Health at the Harvard T.H. Chan School of Public Health, will receive the 2015 Environmental Health Award from the American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE).

Dr. Spengler, was selected for the award to recognize his excellence in volunteer service focused on environmental health issues.

Dr. Spengler is one of the foremost ambient and indoor air experts in the country, with more than 30 years of experience in developing and managing large-scale, multidisciplinary studies to assess human exposures to environmental pollutants. He has developed innovative sampling and analysis methods, large-scale personal monitoring studies, and receptor modeling techniques. He is a member of numerous professional organizations, is widely published in peer-reviewed literature, and continues to frequently present his ground-breaking work at conferences around the world.

ASHRAE, founded in 1894, is a global society advancing human well-being through sustainable technology for the built environment. The Society and its members focus on building systems, energy efficiency, indoor air quality, refrigeration and sustainability within the industry. Dr. Spengler has been a member of ASHRAE since 2000.

Dr. Spengler will travel to the Society’s annual conference in Atlanta, Georgia, on June 27, 2015, to receive the award.

About EH&E

EH&E a leading provider of environmental and engineering consulting services, guarantees that its application of science and engineering best practices will deliver measurable, quantifiable benefits in all aspects of the built environment. EH&E’s focus on evidence-based decision making and advanced capabilities in analytics and technology innovation help its clients achieve and quantify optimal performance from their people and assets. For more information, visit the EH&E website at www.eheinc.com.

Notes to Editors:

 

Tags: , , , , , ,


B2B News is proudly powered by WordPress.
WordPress